PT2054406E - Nucleósidos para suprimir ou reduzir o desenvolvimento de resistência em terapia citostática - Google Patents

Nucleósidos para suprimir ou reduzir o desenvolvimento de resistência em terapia citostática Download PDF

Info

Publication number
PT2054406E
PT2054406E PT77866689T PT07786668T PT2054406E PT 2054406 E PT2054406 E PT 2054406E PT 77866689 T PT77866689 T PT 77866689T PT 07786668 T PT07786668 T PT 07786668T PT 2054406 E PT2054406 E PT 2054406E
Authority
PT
Portugal
Prior art keywords
nucleosides
suppressing
development
resistance
reducing
Prior art date
Application number
PT77866689T
Other languages
English (en)
Inventor
Rudolf Fahrig
Dieter Lohmann
Andreas Rolfs
Henrik Dieks
Janek Teubner
Jörg-Christian Heinrich
Original Assignee
Resprotect Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resprotect Gmbh filed Critical Resprotect Gmbh
Publication of PT2054406E publication Critical patent/PT2054406E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
PT77866689T 2006-08-11 2007-08-13 Nucleósidos para suprimir ou reduzir o desenvolvimento de resistência em terapia citostática PT2054406E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006037786A DE102006037786A1 (de) 2006-08-11 2006-08-11 Nukleoside, diese enthaltendes Arzneimittel und deren Verwendung

Publications (1)

Publication Number Publication Date
PT2054406E true PT2054406E (pt) 2015-11-30

Family

ID=38537796

Family Applications (1)

Application Number Title Priority Date Filing Date
PT77866689T PT2054406E (pt) 2006-08-11 2007-08-13 Nucleósidos para suprimir ou reduzir o desenvolvimento de resistência em terapia citostática

Country Status (16)

Country Link
US (1) US8492537B2 (pt)
EP (1) EP2054406B1 (pt)
JP (1) JP5461989B2 (pt)
KR (1) KR101113029B1 (pt)
CN (1) CN101522666B (pt)
AU (1) AU2007283729B2 (pt)
BR (1) BRPI0716425A2 (pt)
CA (1) CA2660636C (pt)
DE (1) DE102006037786A1 (pt)
DK (1) DK2054406T3 (pt)
ES (1) ES2553404T3 (pt)
HU (1) HUE028077T2 (pt)
MX (1) MX2009001433A (pt)
PL (1) PL2054406T3 (pt)
PT (1) PT2054406E (pt)
WO (1) WO2008017515A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2515650A4 (en) * 2009-12-23 2013-05-29 Univ Nebraska TARGETED RADIOMARTICATED COMPOUNDS AND THEIR USE FOR THE TREATMENT AND DIAGNOSIS OF CANCER
US9073960B2 (en) 2011-12-22 2015-07-07 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN105934438A (zh) 2013-11-27 2016-09-07 艾登尼克斯药业有限公司 用于治疗肝癌的核苷酸
CN107540718B (zh) * 2017-10-26 2020-01-31 天津立博美华基因科技有限责任公司 1-（2-脱氧-β-D-呋喃核糖基）-5-碘-2-嘧啶酮的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8100177A (nl) 1981-01-15 1982-08-02 Stichting Rega V Z W 3'-amino- of -azidoderivaten van e-5-(2-halogeenvinyl)-2'-deoxyuridine.
HU183567B (en) 1981-09-07 1984-05-28 Mta Koezponti Kemiai Kutato In Process for preparing /e/-5-/2-bromo-vinyl/-uridine and derivatives thereof
EP0097039A1 (en) 1982-06-16 1983-12-28 Beecham Group Plc 5-(E-2-halovinyl)-2'-deoxyuridine derivatives, processes for their preparation, pharmaceutical compositions containing them, and their use in treating viral infections
EP0104857A1 (en) * 1982-09-28 1984-04-04 Beecham Group Plc Deoxyuridine compounds, methods for preparing them and their use in medicine
US4724232A (en) 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
ZA867013B (en) 1985-09-17 1988-04-27 Wellcome Found Therapeutic nucleosides
US5010176A (en) 1988-11-10 1991-04-23 Eli Lilly And Company Antibody-drug conjugates
GB8912972D0 (en) 1989-06-06 1989-07-26 Wellcome Found Therapeutic nucleosides
DD288827A5 (de) 1989-11-07 1991-04-11 Adw Zi F. Molekularbiologie,De Verfahren zur herstellung von 5-vinyl-analoga des 2',3'-diedesoxy-3'-fluoruridins
EP0806956B1 (de) 1995-02-01 2002-08-28 RESprotect GmbH Verwendung von 5' substituierten nukleosiden zur hemmung von resistenzbildung bei der zytostatikabehandlung
DE19545892A1 (de) * 1995-12-08 1997-06-12 Fraunhofer Ges Forschung Verwendung von (E)-5-(2-Bromovinyl-)-2'-deoxyuridine (BVDU) zur Resistenzbildung bei der Zytostatikabehandlung und Arzneimittel, enthaltend BVDU
EP0994715A4 (en) 1997-03-24 2001-08-08 Lilly Co Eli DIFLUORONUCLEOSIDE-PHOSPHONIC ACIDS AND DERIVATIVES THEREOF
PT1045897E (pt) * 1998-01-23 2002-07-31 Newbiotics Inc Agentes terapeuticos por catalise enzimatica
KR101195019B1 (ko) * 2000-10-18 2012-10-29 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
US20020147175A1 (en) 2000-11-16 2002-10-10 Shepard H. Michael Synergistic ECTA compositions
DE10108851A1 (de) * 2001-02-23 2002-09-12 Resprotect Gmbh Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten
DE10313035A1 (de) 2003-03-24 2004-10-07 Resprotect Gmbh Methode zur Verstärkung der apoptotischen Wirkung von Zytostatika ohne Erhöhung toxischer Nebenwirkungen
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
EP1674104A1 (en) * 2004-12-24 2006-06-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Uridine derivatives as antiviral drugs against a flaviviridae, especially HCV

Also Published As

Publication number Publication date
KR101113029B1 (ko) 2012-06-05
KR20090040905A (ko) 2009-04-27
PL2054406T3 (pl) 2016-04-29
AU2007283729B2 (en) 2011-09-01
US8492537B2 (en) 2013-07-23
JP5461989B2 (ja) 2014-04-02
AU2007283729A1 (en) 2008-02-14
DE102006037786A1 (de) 2008-03-20
MX2009001433A (es) 2009-04-09
CN101522666A (zh) 2009-09-02
JP2010500307A (ja) 2010-01-07
EP2054406B1 (de) 2015-10-07
US20100227834A1 (en) 2010-09-09
CA2660636A1 (en) 2008-02-14
HUE028077T2 (en) 2016-11-28
DK2054406T3 (en) 2015-11-30
BRPI0716425A2 (pt) 2013-12-03
ES2553404T3 (es) 2015-12-09
CA2660636C (en) 2015-10-06
CN101522666B (zh) 2014-01-22
WO2008017515A1 (de) 2008-02-14
EP2054406A1 (de) 2009-05-06

Similar Documents

Publication Publication Date Title
EP2032168A4 (en) COMBINED THERAPY BASED ON CAPECITABINE
IL196559A0 (en) Combination therapy
IL195731A0 (en) Pyrimidine derivatives useful in the treatment of cancer
GB0625659D0 (en) Therapeutic compounds and their use
EP2062596A4 (en) ANTI-TUMOR AGENT
ZA200901376B (en) Trauma therapy
HK1215683A1 (zh) 抗葉酸藥在癌症治療中的聯合應用
PT2101731T (pt) Endoxifeno para utilização no tratamento de cancro
IL196556A0 (en) Combination therapy
EP2054061A4 (en) COMBINATION THERAPY
IL198723A0 (en) Methods and compositions for therapeutic treatment
PT2054406E (pt) Nucleósidos para suprimir ou reduzir o desenvolvimento de resistência em terapia citostática
PL2012805T3 (pl) Kompozycja lecznicza i jej zastosowanie
PT2061458E (pt) Composições de topiramato e métodos para a sua utilização
HK1183623A1 (en) Antiviral method and composition
GB0607946D0 (en) Mono and combination therapy
IL198026A0 (en) Sequential combination therapy
ZA200902203B (en) Combination therapy
GB2441007B (en) Auricular therapy
GB0606660D0 (en) Targeted Therapy
ZA200810524B (en) Pyrimidine derivatives useful in the treatment of cancer
GB0614538D0 (en) Therapeutic Compounds And Their Use
GB2437719B (en) Body panel insert
GB0601818D0 (en) Therapeutic agent
GB0620514D0 (en) Therapeutic composition